BNP Paribas Financial Markets’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $733K | Buy |
271,634
+245,919
| +956% | +$455K | ﹤0.01% | 3520 |
|
|
2026
Q1 | $30.9K | Sell |
25,715
-3,580
| -12% | -$4.36K | ﹤0.01% | 4934 |
|
|
2025
Q4 | $28.8K | Buy |
29,295
+1,939
| +7% | +$2.33K | ﹤0.01% | 4920 |
|
|
2025
Q3 | $34.5K | Sell |
27,356
-260,056
| -90% | -$280K | ﹤0.01% | 4750 |
|
|
2025
Q2 | $322K | Sell |
287,412
-54,824
| -16% | -$63.7K | ﹤0.01% | 3573 |
|
|
2025
Q1 | $270K | Buy |
342,236
+54,525
| +19% | +$66.8K | ﹤0.01% | 3541 |
|
|
2024
Q4 | $475K | Buy |
287,711
+113,563
| +65% | +$286K | ﹤0.01% | 3344 |
|
|
2024
Q3 | $610K | Buy |
174,148
+161,776
| +1,308% | +$629K | ﹤0.01% | 2772 |
|
|
2024
Q2 | $40.6K | Sell |
12,372
-34,590
| -74% | -$151K | ﹤0.01% | 3502 |
|
|
2024
Q1 | $345K | Buy |
46,962
+23,582
| +101% | +$146K | ﹤0.01% | 3048 |
|
|
2023
Q4 | $87.4K | Sell |
23,380
-217,195
| -90% | -$513K | ﹤0.01% | 3427 |
|
|
2023
Q3 | $510K | Sell |
240,575
-269,228
| -53% | -$892K | ﹤0.01% | 2720 |
|
|
2023
Q2 | $2.43M | Sell |
509,803
-217,684
| -30% | -$1.2M | ﹤0.01% | 1637 |
|
|
2023
Q1 | $4.15M | Buy |
727,487
+450,923
| +163% | +$2.72M | 0.01% | 1357 |
|
|
2022
Q4 | $2.79M | Buy |
276,564
+9,386
| +4% | +$176K | ﹤0.01% | 1587 |
|
|
2022
Q3 | $5.99M | Buy |
267,178
+160,430
| +150% | +$4.64M | 0.01% | 1276 |
|
|
2022
Q2 | $2.65M | Buy |
106,748
+63,223
| +145% | +$1.74M | ﹤0.01% | 1591 |
|
|
2022
Q1 | $1.69M | Sell |
43,525
-26,636
| -38% | -$1.03M | ﹤0.01% | 1951 |
|
|
2021
Q4 | $4.11M | Buy |
70,161
+38,093
| +119% | +$2.16M | 0.01% | 1485 |
|
|
2021
Q3 | $1.9M | Buy |
32,068
+19,442
| +154% | +$1.53M | ﹤0.01% | 1933 |
|
|
2021
Q2 | $1.1M | Sell |
12,626
-1,012
| -7% | -$81.5K | ﹤0.01% | 2133 |
|
|
2021
Q1 | $1.12M | Buy |
13,638
+1,865
| +16% | +$179K | ﹤0.01% | 2076 |
|
|
2020
Q4 | $1.07M | Sell |
11,773
-5,018
| -30% | -$312K | ﹤0.01% | 1981 |
|
|
2020
Q3 | $671K | Sell |
16,791
-97,478
| -85% | -$3.4M | ﹤0.01% | 2039 |
|
|
2020
Q2 | $3.92M | Buy |
114,269
+84,817
| +288% | +$2.53M | 0.01% | 1163 |
|
|
2020
Q1 | $654K | Buy |
29,452
+22,348
| +315% | +$565K | ﹤0.01% | 2200 |
|
|
2019
Q4 | $139K | Sell |
7,104
-1,565
| -18% | -$24.9K | ﹤0.01% | 3129 |
|
|
2019
Q3 | $135K | Buy |
8,669
+1,936
| +29% | +$37.1K | ﹤0.01% | 2951 |
|
|
2019
Q2 | $137K | Sell |
6,733
-5,869
| -47% | -$106K | ﹤0.01% | 2846 |
|
|
2019
Q1 | $221K | Buy |
+12,602
| New | +$199K | ﹤0.01% | 2641 |
|
|
2018
Q4 | – | Sell |
-1,609
| Closed | -$26.2K | – | 4360 |
|
|
2018
Q3 | $26.2K | Hold |
1,609
| – | – | ﹤0.01% | 3308 |
|
|
2018
Q2 | $18.2K | Sell |
1,609
-8,211
| -84% | -$90.5K | ﹤0.01% | 3537 |
|
|
2018
Q1 | $95.8K | Buy |
9,820
+397
| +4% | +$3.8K | ﹤0.01% | 3203 |
|
|
2017
Q4 | $57.6K | Buy |
9,423
+5,702
| +153% | +$25.4K | ﹤0.01% | 3590 |
|
|
2017
Q3 | $14.7K | Sell |
3,721
-276
| -7% | -$938 | ﹤0.01% | 3750 |
|
|
2017
Q2 | $12.9K | Buy |
+3,997
| New | +$15.3K | ﹤0.01% | 3874 |
|
Other funds holding FATE
JJ
BNP Paribas Financial Markets's FATE Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Fate Therapeutics (FATE) stake by 956% in Q2 2026, buying an estimated $455K and bringing the position to 271,634 shares worth $733K. The position accounts for ﹤0.01% of the portfolio, ranked #3520.
BNP Paribas Financial Markets first reported a position in FATE in Q2 2017 and has held it in 36 quarters since. The position peaked at $5.99M in Q3 2022. 141 funds tracked by Wall St. Rank hold FATE as of Q2 2026.
- BNP Paribas Financial Markets held 271,634 shares of Fate Therapeutics worth $733K as of Q2 2026.
- BNP Paribas Financial Markets bought 245,919 Fate Therapeutics shares in Q2 2026, an estimated $455K.
- Fate Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3520 holding.
- BNP Paribas Financial Markets first reported a position in Fate Therapeutics in Q2 2017 and has held it in 36 quarters since.
- BNP Paribas Financial Markets's Fate Therapeutics position peaked at $5.99M in Q3 2022.
- 141 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.